What is Colon Cancer?

Colon cancer, also called colorectal cancer when it includes the rectum, develops in the cells lining the colon. It usually begins as a polyp—a small, benign growth on the inner wall. Over several years, some polyps can become cancerous. Early detection through screening makes treatment far more effective and less invasive.

The colon is the final part of your digestive system, measuring about 5 feet long. Cancer here is common because the colon constantly absorbs water and electrolytes, concentrating waste. This prolonged contact with carcinogens gives abnormal cells time to develop. Most colon cancers start from adenocarcinoma cells, which are found in the lining of the colon.

Colon cancer is one of the most preventable and treatable cancers when caught early. Modern screening methods, improved surgical techniques, and newer chemotherapy drugs have transformed outcomes. In India, awareness remains low, but daycare-based treatment is making quality care more accessible and affordable than ever before.

Types of Colon Cancer

Early Warning Signs

1. Change in bowel habits lasting more than 2–3 weeks Persistent diarrhea, constipation, or alternating patterns suggest something is blocking or irritating the colon.
2. Blood in stool (bright red or dark) Visible blood or changes in stool color are the most common early symptom. Often mistaken for hemorrhoids, but always warrants investigation.
3. Persistent abdominal discomfort—pain, bloating, or cramping Unlike occasional gas pains, cancer-related discomfort returns regularly and may worsen over weeks.
4. Feeling of incomplete emptying after bowel movements Sensation that something remains inside even after a complete bowel movement can signal a blockage.
5. Rectal bleeding or bloody discharge Blood mixed with mucus or stool, or blood without pain, needs prompt colonoscopy evaluation.
6. Unexplained weight loss over weeks Losing 5 kg or more without trying, especially if combined with other symptoms, suggests a serious concern.
7. Persistent fatigue and weakness Anemia from internal bleeding or cancer metabolism can cause exhaustion out of proportion to activity level.
8. Iron deficiency anemia in routine blood work Low iron levels with no obvious cause in someone over 50 warrants colonoscopy to rule out bleeding tumors.
9. Narrow stools (pencil-thin) If stool caliber decreases, a tumor may be narrowing the colon passageway.
10. New onset constipation resistant to fiber and fluids Particularly in middle-aged or older adults, this can indicate a tumor causing mechanical obstruction.

If you notice any of these, see a doctor. In most cases the cause turns out to be benign, but the only way to be sure is an evaluation.

Risk Factors for Colon Cancer

How Colon Cancer is Diagnosed

Cancer Staging (AJCC 8th Edition) (Tumor (T), Node (N), Metastasis (M) classification per AJCC Cancer Staging Manual, 8th Edition)

Staging determines prognosis and guides treatment decisions. Colon cancer is staged after surgery and pathological examination. The stage combines tumor depth (T stage), lymph node involvement (N stage), and distant metastases (M stage).

5-year survival rates are approximate and vary by patient age, comorbidities, molecular subtype (MSI-H vs MSS), and treatment compliance. Individual outcomes may differ. Percentages based on SEER data and major oncology trial results.

Treatment Modalities for Colon Cancer

Surgical Resection

Surgery remains the backbone of curative intent treatment for all stages of colon cancer. The goal is to remove the tumor with adequate margins (typically 5 cm on either side) and sample at least 12 lymph nodes to determine whether cancer has spread. The type of surgery depends on tumor location. Right hemicolectomy removes the cecum, ascending colon, and proximal transverse colon—used for tumors in the right side. Left hemicolectomy removes the distal transverse colon, descending colon, and sigmoid—used for left-sided tumors. Sigmoid colectomy removes just the sigmoid colon when the tumor is in that location.

Modern surgical approaches include laparoscopic (minimally invasive), open, and robotic-assisted techniques. Laparoscopic surgery uses three to four small incisions and a camera, resulting in 2–4 day hospital stays and 2–3 weeks recovery. Open surgery requires a larger incision, 7–10 day stay, and 4–6 week recovery. Robotic surgery offers precision and reduced blood loss, though it’s more expensive (₹1.5–3 lakhs additional). All three approaches achieve equivalent cure rates when performed by experienced colorectal surgeons.

Complete mesocolic excision (CME) is a technique that removes the lymph nodes and fatty tissue around the colon as a single specimen, improving pathological staging and reducing recurrence risk. Patients undergoing elective surgery have better outcomes than emergency surgery (for obstruction or perforation). After surgery, bowel continuity is restored through anastomosis in most cases. Colostomy is rare and necessary only for very low rectal tumors where sphincter preservation is impossible.

• Right hemicolectomy — tumors in cecum, ascending colon, or proximal transverse
• Left hemicolectomy — tumors in distal transverse, descending, or sigmoid colon
• Sigmoid colectomy — tumors confined to sigmoid colon
• Total colectomy — tumors with HNPCC/Lynch syndrome or familial polyposis
• Laparoscopic approach — 2–4 day hospital stay, faster recovery
• Robotic-assisted surgery — improved precision, ₹1.5–3 lakhs additional cost
• Complete mesocolic excision (CME) — improves nodal harvest and staging accuracy

Adjuvant Chemotherapy

Adjuvant chemotherapy is given after surgery to eliminate microscopic disease that may have escaped during the operation or already lodged in lymph nodes. For Stage III colon cancer (lymph node involvement), adjuvant chemotherapy is standard. It reduces recurrence risk by 20–25% and improves overall survival by the same margin. The most commonly used regimen is FOLFOX, given every 2 weeks for 6 months (12 cycles). For patients with poor kidney function or significant neuropathy risk, CAPOX is an alternative, given every 3 weeks for 8 cycles.

For Stage II colon cancer without lymph node involvement, adjuvant chemotherapy is considered if high-risk features are present: T4 tumor (through the entire bowel wall), perforation, fewer than 12 lymph nodes sampled, poorly differentiated grade, MSS status, or elevated CEA. Elderly patients (>75 years) with comorbidities may receive reduced-dose regimens. The treatment can be given as outpatient daycare (FOLFOX with a portable pump) or as oral capecitabine, avoiding hospitalization.

Most patients tolerate adjuvant chemotherapy well with modern supportive care. Oxaliplatin causes peripheral neuropathy in 50% of patients—mild tingling in fingers and toes that resolves in most within months, but 10–15% experience long-term sensory changes. Diarrhea from 5-FU can be significant but is managed with loperamide and dietary adjustment. Bone marrow suppression is monitored with weekly blood counts.

• FOLFOX (5-FU 400 mg/m² bolus + 2400 mg/m² infusion, leucovorin 200 mg/m², oxaliplatin 85 mg/m²) — every 2 weeks × 12 cycles for Stage III
• CAPOX/XELOX (capecitabine 1000 mg/m² twice daily × 14 days, oxaliplatin 130 mg/m² day 1) — every 3 weeks × 8 cycles; alternative to FOLFOX
• 5-FU/LV monotherapy (5-FU 500 mg/m² weekly, leucovorin 20 mg/m²) — for elderly or frail patients
• Capecitabine monotherapy (1250 mg/m² twice daily × 14 days) — for patients not tolerating combination regimens
• FOLFOX or CAPOX for high-risk Stage II — if T4, perforation, <12 nodes, poor differentiation, or MSS

Palliative Chemotherapy for Metastatic Disease

Stage IV colon cancer with distant metastases (liver, peritoneum, lung) is incurable but often treatable. Palliative chemotherapy extends median survival from 6–8 months (without treatment) to 20–30 months, improving quality of life and allowing time for targeted or immunotherapy decisions. The first-line regimen depends on performance status and molecular testing. FOLFOX or FOLFIRI are standard backbone regimens, combined with bevacizumab (an anti-angiogenic agent) or cetuximab (anti-EGFR) if the tumor is KRAS wild-type.

FOLFIRI consists of 5-FU, leucovorin, and irinotecan—a different backbone than FOLFOX that can be used if FOLFOX was given as adjuvant therapy. Irinotecan causes more diarrhea than oxaliplatin and requires careful monitoring for cholinergic side effects (early diarrhea) and late diarrhea (days 2–7). For fit patients with good performance status, triplet chemotherapy (FOLFOXIRI: FOLFOX plus irinotecan) plus bevacizumab can be considered, though toxicity is higher.

Palliative chemotherapy is not meant to cure Stage IV disease, but with modern targeted agents and immunotherapy, some patients achieve sustained remission or even oligometastatic disease amenable to surgery. Treatment is individualized: elderly patients may receive 5-FU monotherapy or capecitabine; young patients with good organs receive full-dose combinations. Cycles continue until disease progression or intolerable toxicity.

• FOLFOXIRI (FOLFOX + irinotecan 165 mg/m²) + bevacizumab — for fit patients, every 2 weeks
• FOLFOX (85 mg/m² oxaliplatin, 5-FU 2400 mg/m² infusion, leucovorin 200 mg/m²) + bevacizumab 5 mg/kg IV — every 2 weeks
• FOLFIRI (irinotecan 180 mg/m², 5-FU 2400 mg/m² infusion, leucovorin 200 mg/m²) + bevacizumab — every 2 weeks; used if FOLFOX toxicity or prior adjuvant FOLFOX
• CAPOX + bevacizumab — every 3 weeks for patients preferring oral 5-FU
• 5-FU/LV monotherapy — for elderly (>75) or frail patients

Anti-VEGF Targeted Therapy (Bevacizumab)

Bevacizumab (Avastin) is a monoclonal antibody against vascular endothelial growth factor (VEGF), a protein that tumors use to build new blood vessels. When added to chemotherapy in metastatic colon cancer, bevacizumab improves overall survival by 5–7 months compared to chemotherapy alone. It is given intravenously with chemotherapy every 2–3 weeks. Cost in India ranges from ₹80,000–1.2 lakhs per infusion, making it a significant expense for Stage IV patients.

Bevacizumab works best in MSS tumors (chemotherapy-responsive) and has less evidence in MSI-H cancers where immunotherapy is preferred. Common side effects include hypertension (30–40% of patients), proteinuria (protein in urine), and rarely, bleeding. Bevacizumab must be held 2 weeks before and after surgery because it increases wound healing complications. Patients over 75 years or with previous thromboembolism require careful risk-benefit discussion. In liver metastases, bevacizumab combined with chemotherapy can sometimes allow downstaging for hepatic resection.

The duration of bevacizumab therapy varies. Some patients continue until disease progression; others stop after 6 months of chemotherapy. There is no established ‘maintenance’ dose that improves survival when given alone. Combination chemotherapy plus bevacizumab is the standard approach.

• Bevacizumab (Avastin) 5 mg/kg IV — every 2 weeks with FOLFOX, FOLFIRI, or CAPOX
• Bevacizumab 7.5 mg/kg IV — every 3 weeks alternative dosing
• Continue with first-line chemotherapy until disease progression or intolerable toxicity
• Discontinue 2 weeks before and after surgery due to wound healing risk
• Cost: ₹80,000–1.2 lakhs per infusion in India

Anti-EGFR Targeted Therapy (Cetuximab / Panitumumab)

Cetuximab (Erbitux) and panitumumab (Vectibix) are monoclonal antibodies against epidermal growth factor receptor (EGFR), used in metastatic colon cancer that is KRAS wild-type. Testing for KRAS, BRAF, and NRAS mutations is mandatory before starting anti-EGFR therapy because mutations confer resistance. Only KRAS wild-type, NRAS wild-type, BRAF wild-type tumors respond to cetuximab. These agents are added to chemotherapy (FOLFOX or FOLFIRI) or used as maintenance monotherapy after chemotherapy.

The main side effect is an acneiform rash in 70–90% of patients—red, itchy papules across the face, chest, and back. While not life-threatening, it is cosmetically and psychologically challenging. Early intervention with topical acne creams (clindamycin lotion, benzoyl peroxide), oral doxycycline or minocycline, and skin care regimens reduce severity. Hypomagnesemia (low blood magnesium) occurs in 50% of patients and requires supplementation. Rare but serious anaphylaxis can occur, particularly in the first infusion.

Cetuximab is given weekly (400 mg/m² loading dose, then 250 mg/m² weekly) or every 2 weeks (500 mg/m² fixed dose). Panitumumab is given every 2 weeks (6 mg/kg). In India, cost ranges from ₹60,000–1.5 lakhs per dose. Anti-EGFR therapy is less commonly used now as immunotherapy has expanded options for MSI-H cancers, but remains standard for KRAS wild-type, MSS metastatic disease.

• Cetuximab 400 mg/m² IV loading dose, then 250 mg/m² weekly — if KRAS wild-type, NRAS wild-type, BRAF wild-type
• Cetuximab 500 mg/m² IV every 2 weeks — alternative dosing (fixed dose)
• Panitumumab 6 mg/kg IV every 2 weeks — alternative to cetuximab, KRAS wild-type only
• Add to FOLFOX or FOLFIRI, or use as maintenance monotherapy after chemotherapy
• Requires RAS/BRAF mutation testing before initiation
• Cost: ₹60,000–1.5 lakhs per dose in India

Immunotherapy for MSI-H/dMMR Tumors

Microsatellite Instability-High (MSI-H) or deficient mismatch repair (dMMR) colon cancers—about 15% of all cases—respond dramatically to immune checkpoint inhibitors. These tumors have thousands of mutations due to defective DNA repair, making them highly visible to the immune system. Pembrolizumab (Keytruda) and nivolumab (Opdivo) are PD-1 inhibitors approved for MSI-H/dMMR metastatic colon cancer. Combined nivolumab plus ipilimumab (anti-CTLA-4) achieves response rates of 40–50%, with some responses lasting years.

For Stage III MSI-H colon cancer, pembrolizumab given adjuvantly (after surgery) significantly improves disease-free survival compared to chemotherapy alone. This represents a paradigm shift for select high-risk patients. Immunotherapy works regardless of KRAS or BRAF mutation status, making it attractive for patients whose tumors would be resistant to anti-EGFR therapy. In India, pembrolizumab costs ₹2.5–4 lakhs per 100 mg dose; nivolumab costs ₹1.5–2.5 lakhs per 240 mg dose.

Side effects are immune-related adverse events (irAEs): colitis (diarrhea, abdominal pain, blood in stool), hepatitis (elevated liver enzymes), pneumonitis (cough, shortness of breath), thyroiditis, and rash. Most irAEs are manageable with corticosteroids and careful monitoring, but severe colitis can be life-threatening. Baseline and periodic screening of liver enzymes, thyroid function, and clinical assessment is mandatory. Patients with active ulcerative colitis or uncontrolled asthma are at higher risk.

• Pembrolizumab 200 mg IV every 3 weeks — adjuvant for Stage III MSI-H or palliative for Stage IV MSI-H
• Nivolumab 240 mg IV every 2 weeks — palliative for MSI-H metastatic disease
• Nivolumab 240 mg IV + ipilimumab 60 mg IV every 3 weeks × 4, then nivolumab monotherapy — for MSI-H/dMMR metastatic
• Pembrolizumab 200 mg IV every 3 weeks, adjuvant continuation for up to 1 year — Stage III MSI-H after surgery
• Cost: pembrolizumab ₹2.5–4 lakhs per dose; nivolumab ₹1.5–2.5 lakhs per dose in India
• Requires MSI/MMR testing; not for MSS tumors

Hepatic Metastasectomy and Ablation

Up to 50% of colon cancer patients develop liver metastases. If metastases are few (1–4 lesions) and resectable, surgical removal of the affected liver segments offers the best chance of cure. Five-year survival after R0 hepatic resection (complete removal with clear margins) is 30–50%, compared to 5–10% for patients treated with chemotherapy alone. This is why hepatic resection is considered whenever feasible, even in patients with synchronous (present at diagnosis) metastases.

Modern hepatic surgery uses minimally invasive laparoscopic or robotic-assisted techniques, reducing hospital stay from 7–10 days to 2–4 days. Preoperative chemotherapy (4–6 months FOLFOX or FOLFIRI plus bevacizumab) downstages larger tumors to resectable size in 40–50% of cases. In India, hepatic resection costs ₹3–6 lakhs depending on extent; combined with perioperative chemotherapy, total cost reaches ₹8–12 lakhs.

For unresectable metastases or patients refusing surgery, percutaneous radiofrequency ablation (RFA) or microwave ablation can treat solitary or small metastases. RFA is less invasive—ultrasound or CT-guided needle placement that heats and destroys the tumor. Cost is ₹2–4 lakhs. Local recurrence occurs in 10–20% of ablated lesions, so imaging surveillance is strict. Combination approaches—resection of one large metastasis plus ablation of small ones—are increasingly used.

• Hepatic resection: right or left hepatectomy, segmentectomy, wedge resection — based on location and extent
• Preoperative chemotherapy: FOLFOX or FOLFIRI + bevacizumab × 4–6 months — to downstage and improve resectability
• Radiofrequency ablation (RFA) — for lesions <3 cm, solitary or up to 3 lesions
• Microwave ablation — alternative to RFA, faster tissue destruction, better for larger lesions
• Hepatic resection cost: ₹3–6 lakhs; total with chemotherapy: ₹8–12 lakhs in India

Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

HIPEC is a technique used when colon cancer has spread to the peritoneum (lining of the abdomen), a condition called peritoneal carcinomatosis. After surgically removing visible tumors, heated chemotherapy solution (typically mitomycin C or doxorubicin at 42–43°C) is infused into the peritoneal cavity for 60–90 minutes, allowing direct drug exposure to residual microscopic disease. HIPEC combined with cytoreductive surgery aims to extend survival from 6 months (median with palliative care alone) to 30–40 months in selected patients.

HIPEC is most effective when peritoneal involvement is limited (completeness of cytoreduction score 1–2 out of 3). It is offered at select high-volume centers in India—major cancer hospitals in Delhi, Mumbai, and Bangalore. The procedure carries significant morbidity: prolonged surgery (6–10 hours), anastomotic leak risk, and bowel dysfunction. Patient selection is critical: only those <75 years, good performance status, no prior extensive abdominal surgery, and limited metastatic disease are candidates.

In India, HIPEC is not widely available and costs ₹5–8 lakhs including hospitalization and chemotherapy. Randomized trials (PRODIGE 7) show HIPEC plus cytoreductive surgery improves survival for limited peritoneal carcinomatosis, but not for extensive disease. Long-term outcomes data in Indian cohorts is limited. Referral to tertiary centers experienced in peritoneal malignancy is essential.

• Cytoreductive surgery — removal of visible peritoneal metastases and involved viscera
• HIPEC: Mitomycin C 10–15 mg/m² or Doxorubicin 15 mg/m² at 42–43°C — 60–90 minutes intraperitoneal infusion
• Postoperative intraperitoneal chemotherapy (EPIC) — optional early postoperative infusion
• Available at select tertiary centers; cost ₹5–8 lakhs in India

Radiation Therapy

Radiation is not standard for colon cancer because the colon is mobile and difficult to target precisely, and the small bowel toxicity risk is high. However, radiation is used selectively: (1) for locally recurrent colon cancer after prior surgery, (2) for solitary distant metastases (brain, adrenal, lung) that cannot be resected, and (3) rarely, for pain relief in advanced disease. Intensity-modulated radiation therapy (IMRT) or stereotactic body radiation therapy (SBRT) allows high doses to tumors with sparing of surrounding normal tissue.

For brain metastases from colon cancer, whole-brain radiation (30 Gy in 10 fractions) was traditionally used, but is now reserved for patients with many lesions. Single brain metastases are treated with stereotactic radiosurgery (SRS)—a single high dose of radiation delivered to the tumor in one session. SRS controls 80–90% of brain metastases and avoids neurocognitive decline from whole-brain radiation. Lung metastases <3 cm may be treated with stereotactic body RT (SBRT, also called CyberKnife).

Cost of radiation therapy in India: IMRT course (25–30 fractions) costs ₹1.5–3 lakhs; SRS ₹1–2 lakhs per lesion; SBRT for lung metastases ₹2–4 lakhs. Radiation is combined with systemic chemotherapy and targeted agents. Late effects (bowel stricture, secondary malignancies) are rare with modern techniques but require years of monitoring.

• Intensity-modulated radiation therapy (IMRT): 50–66 Gy in 25–30 fractions — for locally recurrent disease, 5 days/week
• Stereotactic body radiation therapy (SBRT/CyberKnife): 20–30 Gy in 3–5 fractions — for oligometastatic disease (lung, adrenal metastases)
• Stereotactic radiosurgery (SRS): single dose 15–20 Gy — for solitary brain metastases <4 cm
• Whole-brain radiation: 30 Gy in 10 fractions — for multiple (>4) brain metastases
• Cost: IMRT ₹1.5–3 lakhs; SRS ₹1–2 lakhs per lesion; SBRT ₹2–4 lakhs in India

Neoadjuvant Chemotherapy for Locally Advanced Disease

Neoadjuvant chemotherapy—chemotherapy given before surgery—is standard practice for rectal cancer but is used selectively in colon cancer when the tumor is locally advanced, invading adjacent structures (T4b), or has fixed lymph node involvement. Neoadjuvant therapy shrinks the tumor, making surgery safer and more R0 (complete removal). For stage III colon cancer with borderline resectability, 3–4 months of FOLFOX or FOLFIRI plus bevacizumab is given first, followed by reassessment with imaging and surgery.

Neoadjuvant chemotherapy is also used to downstage patients with synchronous metastases. Converting unresectable oligometastatic disease to resectable (via tumor shrinkage) can lead to cure. For example, a patient with a T4 colon tumor and 2–3 small liver metastases receives 4–6 months FOLFOX plus bevacizumab, then surgery to remove the primary and resect hepatic metastases if now feasible. Response rate is 40–60%, and patients with partial response achieve significantly better survival than those with stable disease.

The risk of neoadjuvant chemotherapy is treatment-related toxicity before surgery: diarrhea, neutropenia, or neuropathy may force dose reductions or treatment delays. However, fit patients tolerate it well. Surgery is performed 2–4 weeks after completing chemotherapy, allowing recovery from bone marrow suppression. Pathological response is assessed post-surgery and guides post-operative adjuvant decisions.

• FOLFOX (5-FU 2400 mg/m² infusion, oxaliplatin 85 mg/m², leucovorin 200 mg/m²) + bevacizumab 5 mg/kg — every 2 weeks × 6–8 cycles
• FOLFIRI (5-FU 2400 mg/m² infusion, irinotecan 180 mg/m², leucovorin 200 mg/m²) + bevacizumab — every 2 weeks × 6–8 cycles
• CAPOX (capecitabine 1000 mg/m² BID × 14 days, oxaliplatin 130 mg/m² day 1) × 4–6 cycles — alternative
• Followed by surgery 2–4 weeks after last cycle
• Restaging imaging (CT or MRI) at cycle 3–4 to assess response and resectability

Supportive and Palliative Care

Palliative care is not end-of-life care; it begins at diagnosis and runs parallel to curative treatment. It focuses on symptom management, quality of life, pain control, nutritional support, and psychological well-being. For advanced colon cancer causing obstruction or perforation, emergency interventions (colostomy, bowel resection) may be needed. For patients with metastatic disease, palliative chemotherapy extends survival, but a clear treatment goal—curative, life-prolonging, or comfort-focused—guides decisions.

Symptom management includes: diarrhea control (loperamide, octreotide), constipation relief (stool softeners, laxatives), pain management (WHO stepwise approach with opioids for severe pain), nutritional supplementation (protein drinks, tube feeding if swallowing impaired), and psychosocial support (counseling, support groups, financial assistance). In India, palliative care infrastructure is improving; organizations like the Indian Society for Study of Pain and regional hospices provide care. Cost of supportive care ranges from ₹2–5 lakhs for the final year of life.

Advance directives and end-of-life planning are important conversations. Many patients with advanced cancer benefit from hospice care at home, where comfort, dignity, and family time are prioritized. Do-not-resuscitate (DNR) orders and preferences around aggressive interventions should be documented. Palliative care teams (oncologists, nurses, social workers, psychologists, dietitians) coordinate holistic support, improving both quality of life and paradoxically, median survival in some studies.

• Loperamide 2 mg three to four times daily — for diarrhea from chemotherapy or bowel resection
• Octreotide 100–150 mcg IV/SC three times daily — for refractory diarrhea or secretory complications
• Morphine immediate-release 5–10 mg every 4 hours, or long-acting formulations — for cancer pain
• Prochlorperazine 5–10 mg every 4–6 hours or metoclopramide 10 mg before meals — for nausea and vomiting
• Nutritional supplements: Ensure, Nutribullet, or nasogastric tube feeding — to maintain protein and calorie intake
• Counseling, social work, and dietitian support — included in comprehensive palliative care

Why Adjuvant Chemotherapy Matters for Stage III Colon Cancer

Even after successful surgery appears to remove all visible cancer, microscopic tumor cells often escape into the bloodstream during the operation or were already in lymph nodes. Adjuvant chemotherapy—drugs given after surgery—circulates through the body to catch and kill these hidden cancer cells before they establish themselves as recurrent tumors. For Stage III colon cancer (positive lymph nodes), adjuvant chemotherapy reduces the risk of recurrence by 20–25% and improves overall survival by a similar margin.

The evidence is overwhelming. Large randomized trials like MOSAIC (testing FOLFOX in Stage III) and ACCENT showed that patients who received chemotherapy after surgery lived longer and stayed cancer-free longer than those who had surgery alone. For high-risk Stage II patients—those with poor prognostic features like invasion through the bowel wall or inadequate lymph node sampling—chemotherapy is increasingly recommended. The decision to treat is personalized based on age, kidney function, neuropathy risk, and whether the tumor has predictive biomarkers.

The goal of adjuvant therapy is curative, not palliative. Most patients who complete six months of chemotherapy and remain disease-free five years later are likely cured. That’s why the temporary side effects of chemotherapy are worth it. In India, where advanced disease is still common at presentation, catching and treating Stage III disease aggressively before metastases develop is critical to improving survival rates.

A Day at HealOnco: What to Expect

Treatment Costs in India

Our Colon Cancer Specialists

Our Centres

Modern Treatment vs. Traditional Approach

Managing Treatment Side Effects

Every cancer treatment can cause side effects. Your oncologist will explain what to expect based on your specific treatment plan and how the team will manage any issues that arise. Common concerns include fatigue, nausea, and changes in blood counts — all of which are closely monitored at HealOnco.

Read the full side effects guide for Colon Cancer →

What Our Patients Say

Patient Stories

Video testimonials coming soon. We are working with patients who have completed treatment and are willing to share their journey on camera.

Frequently Asked Questions

Colon Cancer Treatment in Top Cities

Colon Cancer Treatment Cost by City

Cost pages for each city are being prepared and will link here once live. In the meantime, email info.healonco@gmail.com with your diagnosis details for a city-specific estimate.

Related Cancers We Treat

Supportive Care at HealOnco

References

1. GLOBOCAN 2020. Global Cancer Observatory: Cancer Today. World Health Organization, International Agency for Research on Cancer. https://gco.iarc.who.int/
2. National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program. https://seer.cancer.gov/
3. Indian Council of Medical Research (ICMR). National Centre for Disease Informatics and Research. Cancer Registry Program. https://www.icmr.gov.in/
4. André T, de Gramont A, Vernerey D, et al. Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colorectal cancer: updated 10-year survival and meta-analysis of MOSAIC trial. J Clin Oncol. 2015;33(35):4176–4183. doi:10.1200/JCO.2015.63.4238
5. Kuebler JP, Wieand HS, O’Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP protocol C-07. J Clin Oncol. 2007;25(23):3456–3461.
6. Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–413. doi:10.1126/science.aan6733
7. Cercek A, Lumish M, Sinopoli J, et al. PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Colorectal Cancer. N Engl J Med. 2022;386(25):2363–2376. doi:10.1056/NEJMoa2201445
8. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355(9209):1041–1047.
9. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26(12):2013–2019. doi:10.1200/JCO.2007.14.9930
10. Watanabe T, Muro K, Ajioka Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2020;25(1):1–42.
11. Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Prz Gastroenterol. 2019;14(2):89–103. doi:10.5114/pg.2018.81072
12. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Colon Cancer. Version 4.2025. https://www.nccn.org/